CAS: 15686-51-8; (R)-2-(2-((R)-1-(4-Chlorophenyl)-1-Phenylethoxy)Ethyl)-1-Methylpyrrolidine

上下游产品

(R)-2-[2-[1-(4-Chlorophenyl)-1-Phenylethoxy]Ethyl]-1-Methylpyrrolidine 1174565-35-5
(R)-1-(4-Chlorophenyl)-1-Phenylethanol 117605-76-2

📜(R)-2-(2-Chloroethyl)-1-Methylpyrrolidine Hydrochloride置于sodium Hydride,Potassium Hydroxide体系中,用 5,5-Dimethyl-1,3-Cyclohexadiene,水,Mineral Oil 用作溶剂,化学反应 4.17H,反应生成富马酸氯马斯汀
参考文献:H1受体拮抗剂(R,R)-Clemastine的不对称合成
标题:H1受体拮抗剂(R,R)-Clemastine的不对称合成
摘要:(R,R)-Clemastine (1) 的第一个不对称合成是通过 (R)-叔醇 2 和 (R)-氯乙基吡咯烷 3 通过 O-烷基化的偶联完成的.(R)-叔醇 2 是通过手性 α-苄氧基酮与格氏试剂通过螯合控制的 1,4-不对称诱导立体选择性烷基化合成的.在反应中,手性苄基作为手性助剂和保护基团.(R)-氯乙基吡咯烷 3 是通过从 L-高丝氨酸内酯开始的不对称转化制备的,其中外消旋化最小化 N-烯丙基化和闭环复分解作为关键步骤.
Doi:10.1007/s12272-015-0641-4

专利信息

专利号:US-7919505-B2
优先权日:2006-07-11
标题 :Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
发明人：TING PAULINE C; LEE JOE F; FENG KUNG-I; REEDER MICHAEL R; TRZASKA SCOTT T; ZHU MAN; MAO CHEN; FILIPOV DIMITAR L; ZARKADAS DIMITRIOS N
权利人:SCHERING CORP
摘要:The present invention relates to the compound of the formula n nTo methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人：PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:US-2011003780-A1
优先权日:2007-07-10
标题:Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof
发明人：ZHU MAN
权利人:SCHERING CORP
摘要:The present invention relates to the compound of the Formula I: n n n n n n n n n n and to methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to a particular crystalline form and processes of synthesis of the crystalline form. n IM=105109

专利号:US-7402670-B2
优先权日:2004-09-30
标 题:Synthesis by chiral diamine-mediated asymmetric alkylation
发明人：DENG XIAOHU; MANI NEELAKANDHA
权利人:JANSSEN PHARMACEUTICA NV
摘要:Chiral synthesis from an achiral starting material by chiral diamine-mediated, such as sparteine-mediated, intermolecular asymmetric alkylation with a strained cyclic ether in the presence of a Lewis acid.

专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

专利号:US-11918657-B2
优先权日:2017-11-10
标 题 :Dendrimer delivery system and methods of use thereof
发明人：RANGARAMANUJAM KANNAN; SHARMA RISHI; SHARMA ANJALI; KANNAN SUJATHA; ZHANG ZHI; KAMBHAMPATI SIVA PRAMODH
权利人:UNIV JOHNS HOPKINS
摘要:Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. Ëœ120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.